 |
|
|
| |
Projections Using Decision-Analytic Modeling of Long-Term Clinical Value of Telaprevir for the Treatment of HCV Patients Who Had Failed Prior Peginterferon/Ribavirin Treatment
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
Baris Deniz, MSc1; Anita J Brogan, PhD2; Jeffrey D Miller, MS3; Sandra E Talbird, MSPH2; James R Thompson, MS2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2RTI Health Solutions, Research Triangle Park, NC, United States; 3RTI Health Solutions, Waltham, MA, United States
|
| |
|
|
|
|
|
